Gregory R. Friberg - 26 Feb 2026 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief R&D Officer
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
26 Feb 2026
Net transactions value
-$381,937
Form type
4
Filing time
26 Feb 2026, 20:39:05 UTC
Previous filing
13 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Friberg Gregory R EVP, Chief R&D Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL /s/ Tae Sang Yoo, Attorney-in-Fact 26 Feb 2026 0002038768

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Sale $381,937 -6,326 -14% $60.38 37,578 26 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.36 to $60.51. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price